Outcome in serous ovarian cancer is not associated with LATS expression

Abstract

BackgroundLarge tumor suppressor (LATS) proteins are putative tumor suppressors and poorly expressed associated with poor outcome in many cancers. A recent immunohistochemistry study showed that LATS protein expression correlated with poor outcome in serous ovarian cancer.Materials and methodsWe analyzed LATS expression in various ovarian cancer transcriptomic data sets and immunohistochemically assessed LATS protein expression in a Swiss ovarian tumor cohort. Results were compared to clinicopathological characteristics and outcome. We also compared LATS protein expression in serous ovarian cancer cell lines to their EMT status (Western blotting) and drug sensitivity (MTT assay).ResultsThe analysis of 15 different transcriptomic data sets showed that LATS2 was associated with poorer outcome, while LATS1 was irrelevant (HR = 1.19 and HR = 1.00, respectively). The TCGA-RNASeqV2 data set showed that low LATS1 and LATS2 were associated with better survival in serous ovarian carcinoma. Despite heterogeneity among the different data sets, LATS expression is not an indicator of survival in serous ovarian cancer and LATS2 expression may even be tumorigenic. LATS expression was neither associated with survival nor with the stage and grade in the Swiss cohort. It was low in cystadenoma, intermediate in carcinoma, and high in borderline tumors and was higher in serous than mucinous ovarian carcinoma. LATS protein expression extent was comparable in epithelial-, intermediate-, and mesenchymal-type ovarian cancer cells and was not associated with drug sensitivity.ConclusionThese results are largely incompatible with a tumor-suppressive function of LATS in ovarian cancer, and LATS protein level is also not an indicator for drug sensitivity and EMT status of ovarian cancer cells.

Long noncoding RNA ATB promotes ovarian cancer tumorigenesis by mediating histone H3 lysine 27 trimethylation through binding to EZH2

“…Epigenetic alteration often leads to dysregulated gene expression. LATS2 is one of the Hippo members, 33 and low LATS2 was associated with better survival in OC 34 . E‐cadherin is one of epithelial‐mesenchymal transformation markers and increased E‐cadherin inhibits cell invasion of OC 35 .…”

High expression of Fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer

“…High-grade serous ovarian cancer (HGSOC) is the most common, aggressive, and fatal type of ovarian cancer. Almost 30% of patients died within ve years of diagnosis (7), mainly because of lack of disease-speci c symptoms, prominent biomarkers, and effective therapy or targeted drugs (8)(9)(10). Despite sharing some similar histological characters and terminology, high-and low-grade SOCs are now acknowledged as two different neoplasms (11).…”

Uncovering the prognostic gene signatures for the improvement of risk stratification in cancers by using deep learning algorithm coupled with wavelet transform

“…It was also proved that ARHGAP5 could be a prognostic marker of gastric cancer [50] and the expression level of it was associated with invasive and migrative ability of nasopharyngeal carcinoma cells [51]. LATS1 is one of family proteins of large tumor suppressor (LATS) and has been proposed to be a tumor suppressor [52]. It had been found that the expression level of LATS1 had decreased in serous ovarian cancer patients but this gene highly expressed in normal ovarian tissue [52,53].…”

“…LATS1 is one of family proteins of large tumor suppressor (LATS) and has been proposed to be a tumor suppressor [52]. It had been found that the expression level of LATS1 had decreased in serous ovarian cancer patients but this gene highly expressed in normal ovarian tissue [52,53]. SLC34A2 was proved to have an evident effect in the progression of several types of cancers, such as in ovarian cancer [54,55], breast cancer and non-small cell lung cancer [56,57].…”